WALTHAM, Mass., March 10, 2025--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and ...

The purpose of this post is to remind issuers that inducement grants do not require shareholder approval, so if they are used correctly, they can help to increase the life expectancy of the equity ...

The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee, or non-employee director, of Repare, as an inducement material to ...

These grants were made under the company's 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

indie Semiconductor (Nasdaq: INDI), an automotive solutions innovator, today announced that it has granted equity awards (the “Inducement Grants”) under its 2023 Inducement Incentive Plan to ...

Cartesian Therapeutics (RNAC) announced the granting of an inducement award to one new employee. On March 3, 2025, the Company issued to this employee an option to purchase 2,650 shares of the ...

The awards were granted pursuant to Lumentum’s 2025 Inducement Equity Incentive Plan. However, such awards will be subject to substantially the same terms and conditions that apply to awards ...

PURCHASE, NY, March 05, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued inducement awards to 21 new employees.

SOUTH SAN FRANCISCO, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on ...

The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of March 3, 2025, and were approved by the compensation committee ...

The Inducement Grant was granted pursuant to Aligos’ 2024 Inducement Plan as an inducement material to this individual entering employment in accordance with Nasdaq Listing Rule 5635(c)(4).

WOBURN, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...